Compare MPU & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPU | LGVN |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 34.0M |
| IPO Year | 2023 | 2021 |
| Metric | MPU | LGVN |
|---|---|---|
| Price | $0.31 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 73.6K | ★ 379.1K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.48 |
| 52 Week High | $4.44 | $1.80 |
| Indicator | MPU | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 23.31 | 49.34 |
| Support Level | N/A | $0.74 |
| Resistance Level | $1.00 | $0.86 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.78 | 78.25 |
Mega Matrix Corp is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.